EVOLUTION study, lutetium PSMA-617, prostate cancer immunotherapy, checkpoint inhibitors, metastatic castration-resistant prostate cancer, EVOLUTION Trial: Ipilimumab/Nivolumab Plus Lutetium-PSMA ...

In part one, Alan Wein is joined by Melissa Kaufman, who chaired the AUA Guideline Committee on Genitourinary Syndrome of Menopause (GSM), to discuss these guidelines. Dr. Kaufman emphasizes the ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

BPH - Read the latest BPH research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

(UroToday.com) The 2025 PSMA and Beyond annual meeting featured an alpha and other radionuclides session and a presentation by Dr. Alfred Morgenstern discussing 212 Pb-PSMA versus 225 Ac-PSMA. Dr.

(UroToday.com) The 2025 ASCO annual meeting featured a penile cancer rapid oral abstract session and a presentation by Dr. Aditya Dhanawat discussing an open label randomized non-inferiority trial ...

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about ...

SNMMI 2025, post-177Lu therapy, WB SPECT/CT, WB SPECT/CT Studies Post Lu 177 Therapy, 177Lu-PSMA SPECT, StarGuide scanner, 177Lu-PSMA-617 radiopharmaceutical therapy.

Bladder Cancer - Read the latest Bladder Cancer research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

ASCO 2025 BULLSEYE trial, Prostate-Specific Membrane Antigen (PSMA) Radioligand Therapy, androgen deprivation therapy (ADT), 177Lu-PSMA-617, PSMAddition.

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.